Prospective Evaluation of Hypofractionated Stereotactic RT Using CyberKnife for Patients With Prostate Cancer

Inclusion Criteria: * men from 40 to 75 years of age with a confirmed adenocarcinoma prostate, prostate biopsy will be performed \<180 days prior to the randomization date, * completed assessment of tumor differentiation according to Gleason grading allows to perform stratification; * general Performance Status according to the Eastern Cooperative Oncology Group (ECOG) classification ( 0 -1), * belonging to the group of low and intermedium risk of progression; (cT1-cT2c, Gleason 7, PSA to 19.9 ng / ml), cT specified by AJCC 7 Edition (appendix 2), * PSA marked at least 10 days after or before the biopsy, and for patients taking phytosterol 30 days after discontinuation, * no distant metastases, * signing informed consent, * morphological and biochemical blood parameters within the normal limits. Exclusion Criteria: * the presence of active cancer, except skin cancer preceding period 5 years prior to randomization, * surgical treatment (radical prostatectomy) or RT in the pelvic area, * co-morbidities that may significantly affect the expectancy life of the patients * do not meet the criteria for inclusion.